Study: J&J's ceftobiprole works against diabetic foot infection

10/8/2007 | Boston Globe (tiered subscription model), The

Johnson & Johnson reports its ceftobiprole is effective in treating diabetic foot infection in 86% of patients, based on data from Phase III clinical trials. The drug, which is being co-developed by J&J with Basilea Pharmaceutica Ltd., also appeared to work against infections caused by Staphylococcus aureus in some cases, the company reports.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA